Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CURO25 versus CURO35 surfactant threshold trial in preterm neonatal RDS
2019-002923-13Phase 4Terminated
- Sponsor
- Azienda Ospedaliero-Universitaria delle Marche
- Start
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Poractant alfa in respiratory distress syndrome (RDS) (2 arms), sponsored by Azienda Ospedaliero-Universitaria delle Marche. Primary endpoint: Respiratory function defined as oxygen saturation/FiO2 ratio. Started Oct 2020; status: terminated.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on 2019-002923-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002923-13.